November 29, 2017
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Launches New Formulations in Japan
of L-Cartin® for Carnitine Deficiencies
- The three new formulations of L-Cartin are FF 10% liquid solution in 5 mL and 10 mL doses in aluminum sachets, and L-Cartin FF intravenous 1000 mg in prefilled syringes
Otsuka Pharmaceutical Co., Ltd. will introduce three new formulation of L-Cartin® for the treatment of carnitine deficiencies. L-Cartin FF* 10% liquid solution will be offered in 5 mL and 10 mL doses in aluminum sachets. In addition, L-Cartin FF will be offered in an intravenous 1000 mg dose in prefilled syringes.
The three new formulations have been listed on the Japanese National Health Insurance Drug Price List as of November 29, based on the efficacy and function of the drug in carnitine deficiency. The two L-Cartin FF liquid solutions are scheduled for launch on December 4 and the L-Cartin FF intravenous syringe is scheduled for launch on December 20, 2017.
The availability of L-Cartin in liquid-solution formulations in aluminum sachets will offer lightweight and easy-to-handle treatment delivery options. In addition, the availability of prefilled syringes will offer safe and convenient administration to patients in healthcare delivery settings.
- FF (free-form) levocarnatine is the unchlorinated form of leocarnatine
Information in this news release was current as of the original release date.